TABLE OF CONTENTS
Volume 1, Issue 1 (October 2003)
Top of page
Top of page
Top of page
Editorial
Top of pagePapers
Papers: The generics R&D challenge: Seeking the elusive profit margin
Neal Hansen and Paul Tunnah
J Generic Med 1: 6-12; doi:10.1057/palgrave.jgm.4940012
Maximising profitability through commercially successful implementation of over-the-counter switches
Richard Eggleston and Lindsay Bruce
J Generic Med 1: 13-20; doi:10.1057/palgrave.jgm.4940013
Pharmaceutical pricing: Overview of the impact of genericisation
Adam Barak
J Generic Med 1: 21-30; doi:10.1057/palgrave.jgm.4940014
Reference prices and generic medicines: What can we expect?
Jorge Mestre-Ferrandiz
J Generic Med 1: 31-38; doi:10.1057/palgrave.jgm.4940015
The pursuit of distinction: The method of developing the non-proprietary name
R John Fidelino
J Generic Med 1: 39-47; doi:10.1057/palgrave.jgm.4940016
Data protection in the pharmaceutical industry
Paul Ranson
J Generic Med 1: 48-56; doi:10.1057/palgrave.jgm.4940017
Extending the monopoly — How 'secondary patents' can be used to delay or prevent generic competition upon expiry of the basic product patent
Mike Hutchins
J Generic Med 1: 57-71; doi:10.1057/palgrave.jgm.4940018
Protection and challenge of pharmaceutical patents
Attila Mándi
J Generic Med 1: 72-82; doi:10.1057/palgrave.jgm.4940019
US Legal and Regulatory Update
Revised FDA rules regarding Orange Book listings under the Hatch-Waxman Act
J Generic Med 1: 83-87; doi:10.1057/palgrave.jgm.4940020
